Sedative-Hypnotics: Insomnia Pharmacology, CBT-I and Medication Safety

Medical education review updated 10 November 2026. Information is educational; treatment requires individualized clinical assessment and locally approved products.

Overview

Sedative-hypnotic drugs decrease wakefulness or promote sleep, but chronic insomnia should first be evaluated for medical, psychiatric, circadian and sleep-related breathing contributors. Cognitive behavioral therapy for insomnia (CBT-I) is recommended as first-line management. Medication selection, when needed, should be short-term or periodically reassessed and based on sleep complaint and adverse-effect risk [1–3].

Pharmacologic groups

  • Benzodiazepine-receptor agonists: temazepam and triazolam are benzodiazepines; zolpidem, zaleplon and eszopiclone are nonbenzodiazepine ‘Z-drugs’ that enhance GABA-A activity.
  • Orexin receptor antagonists: suvorexant, lemborexant and daridorexant block orexin-mediated wake signaling.
  • Melatonin pathway: ramelteon is a melatonin MT1/MT2 receptor agonist, distinct from GABAergic hypnotics.
  • Low-dose doxepin: predominantly H1 antihistamine activity at sleep doses and can assist sleep maintenance.
  • Other sedating drugs: trazodone, quetiapine and diphenhydramine are not preferred routine chronic-insomnia medications because of limited evidence and/or harms [1,2].

Guideline position

The 2025 VA/DoD guideline recommends CBT-I over medication as initial treatment and suggests low-dose doxepin, dual orexin receptor antagonists or selected Z-drugs when a course of medication is appropriate. It suggests against benzodiazepines, diphenhydramine, trazodone and antipsychotics for routine chronic insomnia. A 2026 AASM guideline conditionally favors CBT-I plus medication over medication alone, but does not find it preferable to CBT-I alone [2,3].

Pharmacokinetic distinctions

Zaleplon has a relatively brief action and is generally aimed at sleep initiation; longer-lasting hypnotics may improve sleep maintenance but increase next-day impairment. Zolpidem clearance and exposure differ among patients and formulations, and next-morning driving impairment can occur. Orexin antagonists differ in metabolism and drug interactions (commonly CYP3A). Ramelteon is metabolized largely hepatically; strong CYP inhibitors and other interacting drugs affect selection [1].

Major safety warnings

Z-drugs carry FDA boxed warnings for complex sleep behaviors, including sleepwalking, sleep-driving and related injury. GABAergic hypnotics increase risks of falls, confusion, amnesia and respiratory suppression when combined with opioids or alcohol. Orexin antagonists are contraindicated in narcolepsy; adverse effects include somnolence and possible sleep paralysis or abnormal dreams. Benzodiazepines carry additional dependence and withdrawal risks; avoid abrupt cessation after prolonged use [1,2].

Clinical practice

Identify sleep-onset versus maintenance complaints, assess sleep apnea and daytime impairment, review alcohol/caffeine/medications, and use shared decision-making about CBT-I access and medicine duration. Sleep-hygiene advice alone is not an adequate substitute for structured CBT-I [2,3].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. US Department of Veterans Affairs and Department of Defense. Clinical practice guideline for management of chronic insomnia disorder and obstructive sleep apnea. 2025. Available from: https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf
  3. American Academy of Sleep Medicine. Combination treatment for chronic insomnia disorder in adults: clinical practice guideline. J Clin Sleep Med. 2026. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC13076838/
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *